Systematic Review of Pertussis: Trends, Challenges, and Advances in Care and Prevention
DOI:
https://doi.org/10.12775/JEHS.2025.79.58216Keywords
Bordetella pertussis, Pertussis, Pertussis Diagnosis, Pertussis Epidemiology, Pertussis Prevention, Pertussis Treatment, pertussis vaccinationAbstract
Pertussis, or whooping cough, persists as a significant public health issue despite widespread vaccination. This review examines the disease’s epidemiology, clinical challenges, diagnostic advancements, treatment, and prevention. Increasing incidence among adolescents and adults highlights the impact of waning immunity and gaps in vaccine coverage. Early diagnosis remains difficult due to nonspecific symptoms, though tools like PCR have improved detection.
Macrolide antibiotics are the mainstay of treatment, but delayed diagnosis reduces their effectiveness. The emergence of antibiotic-resistant Bordetella pertussis strains is concerning. Preventive measures, such as maternal immunization and booster doses, have shown effectiveness but require optimization. Acellular vaccines, while safer than whole-cell vaccines, exhibit waning immunity, prompting research into next-generation vaccines.
This review underscores the need for improved vaccination strategies, public health initiatives to combat vaccine hesitancy, and enhanced global surveillance. Addressing these challenges is vital to reducing pertussis’s burden and improving outcomes, providing critical insights for policy and future research.
References
1. Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017 Sep;17(9):974–80.
2. Cherry JD. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United State: A Comparative study. Curr Probl Pediatr. 1984 Feb;14(2):7–77.
3. Deloria MA, Blackwelder WC, Decker MD, Englund JA, Steinhoff MC, Pichichero ME, et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics. 1995 Sep;96(3 Pt 2):592–4.
4. Esposito S, Stefanelli P, Fry NK, Fedele G, He Q, Paterson P, et al. Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Front Immunol. 2019 Jul 3;10:1344.
5. Howard Ludlam A, Paynter J, Goodyear-Smith F, Petousis-Harris H. Pertussis epidemiology in adults: Retrospective analysis of pertussis incidence and association with comorbidities among adult populations in Aotearoa New Zealand, using national administrative datasets. Vaccine. 2024 Oct 3;42(23):126048.
6. Bahar E, Shamarina D, Sergerie Y, Mukherjee P. Descriptive Overview of Pertussis Epidemiology Among Older Adults in Europe During 2010–2020. Infect Dis Ther. 2022 Oct;11(5):1821–38.
7. Clark TA. Changing Pertussis Epidemiology: Everything Old is New Again. J Infect Dis. 2014 Apr 1;209(7):978–81.
8. Muloiwa R, Kagina BM, Engel ME, Hussey GD. The burden of pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunization (EPI) in 1974: a systematic review protocol. Syst Rev. 2015 Dec;4(1):62.
9. Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-Deficient Bordetella pertussis, Vaccine-Driven Evolution, and Reemergence of Pertussis. Emerg Infect Dis. 2021 Jun;27(6):1561–6.
10. Gaillard ME, Bottero D, Moreno G, Rumbo M, Hozbor D. Strategies and new developments to control pertussis, an actual health problem. Pathog Dis. 2015 Nov;73(8):ftv059.
11. Straney L, Schibler A, Ganeshalingham A, Alexander J, Festa M, Slater A, et al. Burden and Outcomes of Severe Pertussis Infection in Critically Ill Infants*. Pediatr Crit Care Med. 2016 Aug;17(8):735–42.
12. Harrison GJ. Feigin and Cherry’s textbook of pediatric infectious diseases. Eighth edition. Cherry JD, Kaplan SL, Steinbach WJ, Hotez PJ, editors. Philadelphia, PA: Elsevier; 2019.
13. Nguyen VTN, Simon L. Pertussis. Prim Care Clin Off Pract. 2018 Sep;45(3):423–31.
14. Kandeil W, Van Den Ende C, Bunge EM, Jenkins VA, Ceregido MA, Guignard A. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis. Expert Rev Vaccines. 2020 Jul 2;19(7):621–38.
15. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016 Jul;29(3):449–86.
16. MacIntyre CR, De Sousa JC, Heininger U, Kardos P, Konstantopoulos A, Middleton D, et al. Public health management of pertussis in adults: Practical challenges and future strategies. Hum Vaccines Immunother. 2024 Dec 31;20(1):2377904.
17. Papagiannis D, Thireos E, Mariolis A, Katsioulis A, Gartzonika K, Malliaraki N, et al. Pertussis Prevalence in Adult Population in Greece: A Seroprevalence Nationwide Study. Vaccines. 2022 Sep 9;10(9):1511.
18. Guo S, Zhu Y, Guo Q, Wan C. Severe pertussis in infants: a scoping review. Ann Med. 2024 Dec 31;56(1):2352606.
19. Wendelboe AM, Van Rie A. Diagnosis of pertussis: a historical review and recent developments. Expert Rev Mol Diagn. 2006 Nov;6(6):857–64.
20. Wirsing Von König CH. Pertussis diagnostics: overview and impact of immunization. Expert Rev Vaccines. 2014 Oct;13(10):1167–74.
21. World Health Organization. Laboratory Manual for the diagnosis of whooping cough caused by bordetella pertussis/bordetella parapertussis: update 2014. World Health Organization; 2014.
22. Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: Meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Hum Vaccin. 2011 Apr;7(4):481–8.
23. Dragsted DM, Dohn B, Madsen J, Jensen JS. Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions. J Med Microbiol. 2004 Aug 1;53(8):749–54.
24. American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32th edition. Kimberlin DW, Barnett E, Lynfield R, Sawyer MH, editors. Itasca: American Academy of Pediatrics; 2021. 1 p.
25. Carlsson RM, Von Segebaden K, Bergström J, Kling AM, Nilsson L. Surveillance of infant pertussis in Sweden 1998–2012; severity of disease in relation to the national vaccination programme. Eurosurveillance [Internet]. 2015 Feb 12 [cited 2025 Jan 2];20(6). Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES2015.20.6.21032
26. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California Pertussis Epidemic, 2010. J Pediatr. 2012 Dec;161(6):1091–6.
27. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children: Pediatr Infect Dis J. 1995 Oct;14(10):870–3.
28. Carbonetti NH. Bordetella pertussis: new concepts in pathogenesis and treatment. Curr Opin Infect Dis. 2016 Jun;29(3):287–94.
29. Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2005 Dec 9;54(RR-14):1–16.
30. Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2005 [cited 2025 Jan 2]. p. CD004404.pub2. Available from: https://doi.wiley.com/10.1002/14651858.CD004404.pub2
31. Feng Y, Chiu CH, Heininger U, Hozbor DF, Tan TQ, von König CHW. Emerging macrolide resistance in Bordetella pertussis in mainland China: Findings and warning from the global pertussis initiative. Lancet Reg Health West Pac. 2021 Mar;8:100098.
32. Ivaska L, Barkoff AM, Mertsola J, He Q. Macrolide Resistance in Bordetella pertussis: Current Situation and Future Challenges. Antibiot Basel Switz. 2022 Nov 7;11(11):1570.
33. Storsaeter J, Hallander H, Farrington CP, Olin P, Möllby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine. 1990 Oct;8(5):457–61.
34. Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, et al. A Placebo-Controlled Trial of a Pertussis-Toxoid Vaccine. N Engl J Med. 1995 Oct 19;333(16):1045–50.
35. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al. A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis. N Engl J Med. 1996 Feb 8;334(6):341–9.
36. Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol. 2012 May;20(5):211–3.
37. Briga M, Goult E, Brett TS, Rohani P, Domenech De Cellès M. Maternal pertussis immunization and the blunting of routine vaccine effectiveness: a meta-analysis and modeling study. Nat Commun. 2024 Jan 31;15(1):921.
38. Regan AK, Moore HC, Binks MJ, McHugh L, Blyth CC, Pereira G, et al. Maternal Pertussis Vaccination, Infant Immunization, and Risk of Pertussis. Pediatrics. 2023 Nov 1;152(5):e2023062664.
39. Godoy P, García-Cenoz M, Rius C, Muñoz-Almagro C, Carmona G, Alsedà M, et al. Effectiveness of maternal pertussis vaccination in protecting newborn: A matched case-control study. J Infect. 2021 Nov;83(5):554–8.
40. Hozbor D. New Pertussis Vaccines: A Need and a Challenge. In: Fedele G, Ausiello CM, editors. Pertussis Infection and Vaccines [Internet]. Cham: Springer International Publishing; 2019 [cited 2025 Jan 13]. p. 115–26. (Advances in Experimental Medicine and Biology; vol. 1183). Available from: http://link.springer.com/10.1007/5584_2019_407
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wiktor Garbarczyk, Agnieszka Napieralska, Albert Kapla, Alicja Černohorská, Daria Bednarczyk, Julia Białeta, Karolina Siembab, Katarzyna Rowińska, Michalina Jurkiewicz, Wiktoria Pysiewicz
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 28
Number of citations: 0
